| Dr Farhoud Khosravi, DO | |
|
2490 S Woodworth Loop Ste 200, Palmer, AK 99645-7410 | |
| (907) 861-6315 | |
| Not Available |
| Full Name | Dr Farhoud Khosravi |
|---|---|
| Gender | Male |
| Speciality | Gastroenterology |
| Experience | 16 Years |
| Location | 2490 S Woodworth Loop Ste 200, Palmer, Alaska |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1285874362 | NPI | - | NPPES |
| Facility Name | Location | Facility Type |
|---|---|---|
| Mat-su Regional Medical Center | Palmer, AK | Hospital |
| Flagstaff Medical Center | Flagstaff, AZ | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Northern Arizona Healthcare Corporation | 3577473362 | 370 |
| Mat-su Valley Iii Llc | 5496941502 | 30 |
News Archive
Amgen (Nasdaq: AMGN) today announced detailed results from the Phase 3 '181' trial evaluating Vectibix((R)) (panitumumab) in combination with FOLFIRI (an irinotecan based chemotherapy), as a second-line treatment for metastatic colorectal cancer (mCRC). In this trial, Vectibix significantly improved progression-free survival (PFS) in patients with KRAS wild-type mCRC.
Women who take soy or herbal supplements, such as black cohosh, red clover and ginseng, should do so with care, says a Cornell University expert affiliated with the Program on Breast Cancer and Environmental Risk Factors (BCERF) at Cornell, the land-grant institution of New York state.
Health Discovery Corporation announced today it has been selected by MDB Capital Group as one of its Top 50 "Best and Brightest" companies that will present at the invitation-only, 1st Annual Bright Lights Conference, the first public company conference to focus exclusively on companies with disruptive and market changing intellectual property.
Eli Lilly and Company today announced results of three preclinical studies focused on c-MET, a receptor tyrosine kinase that, when it functions normally, plays a key role in transmitting signals within a cell.
› Verified 6 days ago
| Entity Name | Yuma Regional Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1194706655 PECOS PAC ID: 2062314826 Enrollment ID: O20040122000526 |
News Archive
Amgen (Nasdaq: AMGN) today announced detailed results from the Phase 3 '181' trial evaluating Vectibix((R)) (panitumumab) in combination with FOLFIRI (an irinotecan based chemotherapy), as a second-line treatment for metastatic colorectal cancer (mCRC). In this trial, Vectibix significantly improved progression-free survival (PFS) in patients with KRAS wild-type mCRC.
Women who take soy or herbal supplements, such as black cohosh, red clover and ginseng, should do so with care, says a Cornell University expert affiliated with the Program on Breast Cancer and Environmental Risk Factors (BCERF) at Cornell, the land-grant institution of New York state.
Health Discovery Corporation announced today it has been selected by MDB Capital Group as one of its Top 50 "Best and Brightest" companies that will present at the invitation-only, 1st Annual Bright Lights Conference, the first public company conference to focus exclusively on companies with disruptive and market changing intellectual property.
Eli Lilly and Company today announced results of three preclinical studies focused on c-MET, a receptor tyrosine kinase that, when it functions normally, plays a key role in transmitting signals within a cell.
› Verified 6 days ago
| Entity Name | Sjhmc Physician Services |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1326098005 PECOS PAC ID: 4486646197 Enrollment ID: O20040401001189 |
News Archive
Amgen (Nasdaq: AMGN) today announced detailed results from the Phase 3 '181' trial evaluating Vectibix((R)) (panitumumab) in combination with FOLFIRI (an irinotecan based chemotherapy), as a second-line treatment for metastatic colorectal cancer (mCRC). In this trial, Vectibix significantly improved progression-free survival (PFS) in patients with KRAS wild-type mCRC.
Women who take soy or herbal supplements, such as black cohosh, red clover and ginseng, should do so with care, says a Cornell University expert affiliated with the Program on Breast Cancer and Environmental Risk Factors (BCERF) at Cornell, the land-grant institution of New York state.
Health Discovery Corporation announced today it has been selected by MDB Capital Group as one of its Top 50 "Best and Brightest" companies that will present at the invitation-only, 1st Annual Bright Lights Conference, the first public company conference to focus exclusively on companies with disruptive and market changing intellectual property.
Eli Lilly and Company today announced results of three preclinical studies focused on c-MET, a receptor tyrosine kinase that, when it functions normally, plays a key role in transmitting signals within a cell.
› Verified 6 days ago
| Entity Name | Banner Physician Specialists Arizona Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1316228802 PECOS PAC ID: 6204002272 Enrollment ID: O20111222000509 |
News Archive
Amgen (Nasdaq: AMGN) today announced detailed results from the Phase 3 '181' trial evaluating Vectibix((R)) (panitumumab) in combination with FOLFIRI (an irinotecan based chemotherapy), as a second-line treatment for metastatic colorectal cancer (mCRC). In this trial, Vectibix significantly improved progression-free survival (PFS) in patients with KRAS wild-type mCRC.
Women who take soy or herbal supplements, such as black cohosh, red clover and ginseng, should do so with care, says a Cornell University expert affiliated with the Program on Breast Cancer and Environmental Risk Factors (BCERF) at Cornell, the land-grant institution of New York state.
Health Discovery Corporation announced today it has been selected by MDB Capital Group as one of its Top 50 "Best and Brightest" companies that will present at the invitation-only, 1st Annual Bright Lights Conference, the first public company conference to focus exclusively on companies with disruptive and market changing intellectual property.
Eli Lilly and Company today announced results of three preclinical studies focused on c-MET, a receptor tyrosine kinase that, when it functions normally, plays a key role in transmitting signals within a cell.
› Verified 6 days ago
| Entity Name | Tmc Medical Network |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1750832283 PECOS PAC ID: 9638457013 Enrollment ID: O20161107000996 |
News Archive
Amgen (Nasdaq: AMGN) today announced detailed results from the Phase 3 '181' trial evaluating Vectibix((R)) (panitumumab) in combination with FOLFIRI (an irinotecan based chemotherapy), as a second-line treatment for metastatic colorectal cancer (mCRC). In this trial, Vectibix significantly improved progression-free survival (PFS) in patients with KRAS wild-type mCRC.
Women who take soy or herbal supplements, such as black cohosh, red clover and ginseng, should do so with care, says a Cornell University expert affiliated with the Program on Breast Cancer and Environmental Risk Factors (BCERF) at Cornell, the land-grant institution of New York state.
Health Discovery Corporation announced today it has been selected by MDB Capital Group as one of its Top 50 "Best and Brightest" companies that will present at the invitation-only, 1st Annual Bright Lights Conference, the first public company conference to focus exclusively on companies with disruptive and market changing intellectual property.
Eli Lilly and Company today announced results of three preclinical studies focused on c-MET, a receptor tyrosine kinase that, when it functions normally, plays a key role in transmitting signals within a cell.
› Verified 6 days ago
| Entity Name | Northern Arizona Healthcare Corporation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1669914552 PECOS PAC ID: 3577473362 Enrollment ID: O20170801003409 |
News Archive
Amgen (Nasdaq: AMGN) today announced detailed results from the Phase 3 '181' trial evaluating Vectibix((R)) (panitumumab) in combination with FOLFIRI (an irinotecan based chemotherapy), as a second-line treatment for metastatic colorectal cancer (mCRC). In this trial, Vectibix significantly improved progression-free survival (PFS) in patients with KRAS wild-type mCRC.
Women who take soy or herbal supplements, such as black cohosh, red clover and ginseng, should do so with care, says a Cornell University expert affiliated with the Program on Breast Cancer and Environmental Risk Factors (BCERF) at Cornell, the land-grant institution of New York state.
Health Discovery Corporation announced today it has been selected by MDB Capital Group as one of its Top 50 "Best and Brightest" companies that will present at the invitation-only, 1st Annual Bright Lights Conference, the first public company conference to focus exclusively on companies with disruptive and market changing intellectual property.
Eli Lilly and Company today announced results of three preclinical studies focused on c-MET, a receptor tyrosine kinase that, when it functions normally, plays a key role in transmitting signals within a cell.
› Verified 6 days ago
| Entity Name | Arizona Centers For Digestive Health Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1568975316 PECOS PAC ID: 5193083087 Enrollment ID: O20171226000651 |
News Archive
Amgen (Nasdaq: AMGN) today announced detailed results from the Phase 3 '181' trial evaluating Vectibix((R)) (panitumumab) in combination with FOLFIRI (an irinotecan based chemotherapy), as a second-line treatment for metastatic colorectal cancer (mCRC). In this trial, Vectibix significantly improved progression-free survival (PFS) in patients with KRAS wild-type mCRC.
Women who take soy or herbal supplements, such as black cohosh, red clover and ginseng, should do so with care, says a Cornell University expert affiliated with the Program on Breast Cancer and Environmental Risk Factors (BCERF) at Cornell, the land-grant institution of New York state.
Health Discovery Corporation announced today it has been selected by MDB Capital Group as one of its Top 50 "Best and Brightest" companies that will present at the invitation-only, 1st Annual Bright Lights Conference, the first public company conference to focus exclusively on companies with disruptive and market changing intellectual property.
Eli Lilly and Company today announced results of three preclinical studies focused on c-MET, a receptor tyrosine kinase that, when it functions normally, plays a key role in transmitting signals within a cell.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Farhoud Khosravi, DO 2680 S Val Vista Dr, Gilbert, AZ 85295-2152 Ph: () - | Dr Farhoud Khosravi, DO 2490 S Woodworth Loop Ste 200, Palmer, AK 99645-7410 Ph: (907) 861-6315 |
News Archive
Amgen (Nasdaq: AMGN) today announced detailed results from the Phase 3 '181' trial evaluating Vectibix((R)) (panitumumab) in combination with FOLFIRI (an irinotecan based chemotherapy), as a second-line treatment for metastatic colorectal cancer (mCRC). In this trial, Vectibix significantly improved progression-free survival (PFS) in patients with KRAS wild-type mCRC.
Women who take soy or herbal supplements, such as black cohosh, red clover and ginseng, should do so with care, says a Cornell University expert affiliated with the Program on Breast Cancer and Environmental Risk Factors (BCERF) at Cornell, the land-grant institution of New York state.
Health Discovery Corporation announced today it has been selected by MDB Capital Group as one of its Top 50 "Best and Brightest" companies that will present at the invitation-only, 1st Annual Bright Lights Conference, the first public company conference to focus exclusively on companies with disruptive and market changing intellectual property.
Eli Lilly and Company today announced results of three preclinical studies focused on c-MET, a receptor tyrosine kinase that, when it functions normally, plays a key role in transmitting signals within a cell.
› Verified 6 days ago
Rodney S Badger, MD Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 2490 S Woodworth Loop Ste 250, Palmer, AK 99645 Phone: 907-861-6700 Fax: 907-861-6705 | |
Natalie J Beyeler, D.O. Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 1901 N Hemmer Rd Ste 211, Palmer, AK 99645 Phone: 907-745-3770 Fax: 907-745-3780 | |
Dr. Herman H.h. Feringa, M.D., PH.D. Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 2490 S Woodworth Loop Ste 250, Palmer, AK 99645 Phone: 907-561-3211 | |
David Scott Rudolph, MD Gastroenterology Medicare: Not Enrolled in Medicare Practice Location: 561 S Denali, Ste C, Palmer, AK 99645 Phone: 907-745-8432 Fax: 907-746-4489 | |
Dr. Jared Beck, D.O. Gastroenterology Medicare: Medicare Enrolled Practice Location: 2490 S Woodworth Loop Ste 200, Palmer, AK 99645 Phone: 907-861-6315 Fax: 907-861-6533 | |
Martin Earl Cook, DO Gastroenterology Medicare: Medicare Enrolled Practice Location: 2480 S Woodworth Loop Ste 150, Palmer, AK 99645 Phone: 907-861-6312 Fax: 907-861-6322 |